Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4A | P27815 | 2/20 | 0.76 |
| ▸ | PDE4B | Q07343 | 2/20 | 0.76 |
| ▸ | PDE4C | Q08493 | 2/20 | 0.76 |
| ▸ | PDE4D | Q08499 | 2/20 | 0.76 |
| ▸ | PDE5A | O76074 | 7/20 | 0.68 |
| ▸ | PDE2A | O00408 | 1/20 | 0.68 |
| ▸ | PDE1A | P54750 | 1/20 | 0.68 |
| ▸ | PDE1B | Q01064 | 1/20 | 0.68 |
| ▸ | PDE1C | Q14123 | 1/20 | 0.68 |
| ▸ | RHOA | P61586 | 1/20 | 0.51 |
| ▸ | MAPT | P10636 | 3/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.48 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.47 |
| ▸ | POLB | P06746 | 2/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.46 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7417021 | 0.90 | PDE4A (0.62) | PDE4APDE4BPDE4CPDE4DPDE5A | |
| SCHEMBL149748 | 0.86 | PDE4A (1.00) | PDE4APDE4BPDE4CPDE4DPDE5A | |
| SCHEMBL5598718 | 0.86 | PDE4A (0.57) | PDE4APDE4BPDE4CPDE4DPDE5A | |
| SCHEMBL7504141 | 0.86 | PDE4A (0.98) | PDE4APDE4BPDE4CPDE4DPDE5A | |
| SCHEMBL5917665 | 0.86 | PDE4A (0.98) | PDE4APDE4BPDE4CPDE4DPDE5A | |
| Hydrochloric Acid SCHEMBL29801523 | 0.86 | PDE4A (0.98) | PDE4APDE4BPDE4CPDE4DPDE5A | |
| SCHEMBL5917668 | 0.86 | PDE4A (0.98) | PDE4APDE4BPDE4CPDE4DPDE5A | |
| Hydrochloric Acid SCHEMBL7502602 | 0.86 | PDE4A (0.98) | PDE4APDE4BPDE4CPDE4DPDE5A | |
| Potassium SCHEMBL7504150 | 0.86 | PDE4A (0.98) | PDE4APDE4BPDE4CPDE4DPDE5A | |
| SCHEMBL7497369 | 0.85 | PDE4A (0.79) | PDE4APDE4BPDE4CPDE4DPDE5A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 75 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1418896-A2 | ADMINISTRATION OF PHOSPHODIESTERASE INHIBITORS FOR THE TREATMENT OF PREMATURE EJACULATION | Vivus, Inc. (US) | 2004-05-19 | — | — | EP | claimed |
| US-20040087599-A1 | cGMP-PDE inhibitors for the treatment of erectile dysfunction | PFIZER INC | 2004-05-06 | — | — | US | claimed |
| WO-2003000343-A2 | ADMINISTRATION OF PHOSPHODIESTERASE INHIBITORS FOR THE TREATMENT OF PREMATURE EJACULATION | VIVUS, INC. (US) | 2003-01-03 | — | — | WO | claimed |
| US-6469016-B1 | VAGINAL, VULVAR AND/OR URETHRAL ADMINISTRATION OF A PHARMACEUTICAL FORMULATION CONTAINING A VASOACTIVE AGENT TO INCREASE VAGINAL LUBRICATION | VIVUS, INC. | 2002-10-22 | — | — | US | claimed |
| US-20010044441-A1 | 6-heterocyclyl pyrazolo [3,4-d]pyrimidin-4-one cGMP-PDE inhibitors for the treatment of erectile dysfunction | CAMPBELL SIMON FRASER (GB) | 2001-11-22 | — | — | US | claimed |
| EP-0793486-A1 | cGMP-PDE INHIBITORS FOR THE TREATMENT OF ERECTILE DYSFUNCTION | Pfizer Limited (GB) | 1997-09-10 | — | — | EP | claimed |
| WO-1996016644-A1 | cGMP-PDE INHIBITORS FOR THE TREATMENT OF ERECTILE DYSFUNCTION | PFIZER LIMITED (GB) | 1996-06-06 | — | — | WO | claimed |
| US-20150250801-A1 | ANDROGEN PHARMACEUTICAL COMPOSITION AND METHOD FOR TREATING DEPRESSION | BESINS HEALTHCARE LUXEMBOURG SARL (LU) | 2015-09-10 | — | — | US | disclosed |
| US-20150119399-A1 | BETA-CELL REPLICATION PROMOTING COMPOUNDS AND METHODS OF THEIR USE | PRESIDENT AND FELLOWS OF HARVARD COLLEGE | 2015-04-30 | — | — | US | disclosed |
| US-20140142077-A1 | ANDROGEN PHARMACEUTICAL COMPOSITION AND METHOD FOR TREATING DEPRESSION | LABORATORIES BESINS INTERNATIONAL, SAS (FR) | 2014-05-22 | — | — | US | disclosed |
| US-20120283260-A1 | BRADYKININ RECEPTOR AGONISTS AND USES THEREOF TO TREAT OCULAR HYPERTENSION AND GLAUCOMA | ASTELLAS PHARMA INC. (JP) | 2012-11-08 | — | — | US | disclosed |
| US-20120245134-A1 | ANDROGEN PHARMACEUTICAL COMPOSITION AND METHOD FOR TREATING DEPRESSION | DUDLEY ROBERT E (US) | 2012-09-27 | — | — | US | disclosed |
| US-8263555-B2 | Use of bradykinin and related B2R agonists to treat ocular hypertension and glaucoma | ALCON RESEARCH, LTD. (US) | 2012-09-11 | — | — | US | disclosed |
| US-6037346-A | Local administration of phosphodiesterase inhibitors for the treatment of erectile dysfunction | VIVUS, INC. (US) | 2000-03-14 | — | — | US | disclosed |
| WO-1999021558-A2 | LOCAL ADMINISTRATION OF PHOSPHODIESTERASE INHIBITORS FOR THE TREATMENT OF ERECTILE DYSFUNCTION | VIVUS, INC. (US) | 1999-05-06 | — | — | WO | disclosed |
| US-5707998-A | CYCLIC-GMP PHOSPHODIESTERASE INHIBITORS, TREATING CARDIOVASCULAR DISORDERS AND ASTHMA | EISAI CO., LTD. (JP) | 1998-01-13 | — | — | US | disclosed |
| EP-0793486-A1 | cGMP-PDE INHIBITORS FOR THE TREATMENT OF ERECTILE DYSFUNCTION | Pfizer Limited (GB) | 1997-09-10 | — | — | EP | disclosed |
| WO-1996016644-A1 | cGMP-PDE INHIBITORS FOR THE TREATMENT OF ERECTILE DYSFUNCTION | PFIZER LIMITED (GB) | 1996-06-06 | — | — | WO | disclosed |
| EP-0691967-A1 | NITROGEN-CONTAINING FUSED-HETEROCYCLE COMPOUNDS | Eisai Co., Ltd. (JP) | 1996-01-17 | — | — | EP | disclosed |
| WO-1994022855-A1 | NITROGEN-CONTAINING FUSED-HETEROCYCLE COMPOUNDS | EISAI CO., LTD. (JP) | 1994-10-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120283260-A1 | BRADYKININ RECEPTOR AGONISTS AND USES THEREOF TO TREAT OCULAR HYPERTENSION AND GLAUCOMA | BDKRB2, BDKRB1, PTGIR | PDE4A 390/4885PDE4B 649/4885PDE4C 758/4885 |
| US-20040087599-A1 | cGMP-PDE inhibitors for the treatment of erectile dysfunction | PDE3A, PDE5A, PDE2A | PDE4A 5/4885PDE4B 7/4885PDE4C 8/4885 |
| US-20150119399-A1 | BETA-CELL REPLICATION PROMOTING COMPOUNDS AND METHODS OF THEIR USE | IAPP, GPR119, PCNA | PDE4A 1173/4885PDE4B 1204/4885PDE4C 1042/4885 |
| US-20010044441-A1 | 6-heterocyclyl pyrazolo [3,4-d]pyrimidin-4-one cGMP-PDE inhibitors for the treatment of erectile dysfunction | PDE3A, PDE2A, PDE3B | PDE4A 5/4885PDE4B 8/4885PDE4C 7/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.